Evidence map›Paper›PMID 37915310›Full record

ArticleBeilstein journal of nanotechnology2023

Recognition mechanisms of hemoglobin particles by monocytes - CD163 may just be one.

Jonathan-Gabriel Nimz, Pichayut Rerkshanandana, Chiraphat Kloypan, Ulrich Kalus, Saranya Chaiwaree, Axel Pruß, Radostina Georgieva, Yu Xiong, Hans Bäumler

Open access · diamondAbstract read
In one paragraph

Article in Beilstein journal of nanotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Jonathan-Gabriel NimzInstitute of Transfusion Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Pichayut RerkshanandanaInstitute of Transfusion Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0002-1732-7793
Chiraphat KloypanInstitute of Transfusion Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Ulrich KalusInstitute of Transfusion Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Saranya ChaiwareeInstitute of Transfusion Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Axel PrußInstitute of Transfusion Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Radostina GeorgievaInstitute of Transfusion Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0003-1546-5540
Yu XiongInstitute of Transfusion Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Hans BäumlerInstitute of Transfusion Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0002-2573-2289
Charité - Universitätsmedizin Berlin · DEPayap University · THTrakia University · BGUniversity of Phayao · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hemoglobin-based oxygen carriers (HBOCs) as blood substitutes are one of the great hopes of modern transfusion and emergency medicine. After the major safety-relevant challenges of the last decades seem to be largely overcome, current developments have in common that they are affected by degradation and excretion at an early stage in test organisms. Several possible mechanisms that may be responsible for this are discussed in the literature. One of them is CD163, the receptor of the complex of haptoglobin (Hp) and hemoglobin (Hb). The receptor has been shown in various studies to have a direct affinity for Hb in the absence of Hp. Thus, it seems reasonable that CD163 could possibly also bind Hb within HBOCs and cause phagocytosis of the particles. In this work we investigated the role of CD163 in the uptake of our hemoglobin sub-micron particles (HbMPs) in monocytes and additionally screened for alternative ways of particle recognition by monocytes. In our experiments, blockade of CD163 by specific monoclonal antibodies proved to partly inhibit HbMP uptake by monocytes. It appears, however, that several other phagocytosis pathways for HbMPs might exist, independent of CD163 and also Hb.

Indexed as

CD163HBOChemoglobin-based oxygen carriersmonocytesphagocytosis

Identifiers

PMID37915310
PMCPMC10616704
OpenAlexW4387773835

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.